Lnc-ABCA12-8 confers acquired resistance to gefitinib in non-small cell lung cancer by regulating the alternative splicing of fibronectin 1 in the IIICS region

S He, J Shi, HH Zhou, Q Li, L Wu - Cancer Gene Therapy, 2022 - nature.com
Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-
TKIs), such as gefitinib, has dramatically impaired the clinical outcomes in non-small cell …
被引用次数：6 相关文章

Lnc-ABCA12-8 confers acquired resistance to gefitinib in non-small cell lung cancer by regulating the alternative splicing of fibronectin 1 in the IIICS region

S He, J Shi, HH Zhou, Q Li, L Wu - Cancer gene therapy, 2022 - pubmed.ncbi.nlm.nih.gov
Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-
TKIs), such as gefitinib, has dramatically impaired the clinical outcomes in non-small cell …

Lnc-ABCA12-8 confers acquired resistance to gefitinib in non-small cell lung cancer by regulating the alternative splicing of fibronectin 1 in the IIICS region.

S He, J Shi, H Zhou, Q Li, L Wu - Cancer Gene Therapy, 2022 - europepmc.org
Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-
TKIs), such as gefitinib, has dramatically impaired the clinical outcomes in non-small cell …